Outcome of Board Meeting held on August 06, 2026

Emcure Ref: EPL/CS/SE/0064/2026 Date: August 06, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, P J Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai – 400 051 Mumbai- 400 001 Script Symbol: EMCURE Scrip Code/Symbol: 544210/ EMCURE Dear Sir/Madam, Subject: Outcome of Board Meeting held on August 06, 2026. In continuation to our letter dated July 15, 2026, and pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), read with Schedule III of aforesaid Regulations and SEBI Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Thursday, August 06, 2026, has inter-alia transacted and approved/ recommended the following businesses: 1. Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026, as reviewed and recommended by the Audit Committee: In this regard, please find enclosed herewith: a) Pursuant to Regulation 33 of the SEBI Listing Regulations, Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026, along with the Limited Review Reports as issued by M/s. B S R & Co. LLP, Chartered Accountants, Statutory Auditors of the Company, a copy of which is enclosed herewith as Annexure A. b) Press Release outlining key updates on the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026, is also enclosed herewith as Annexure B. 2. Retirement of Director by rotation: The Board noted that Mr. Berjis Desai (DIN: 00153675) Chairman and Non-executive, Non-Independent Director who is liable to retire by rotation, at the ensuing Annual General Meeting (“AGM”) of the Company, has expressed his unwillingness to seek re-appointment due to his appointment as a member of the National Commission for Minorities, New Delhi. Emcure Pharmaceuticals Limited Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251 Emcure Consequently, Mr. Desai shall cease to hold office as a Chairman and Director of the Company, with effect from the conclusion of the ensuing AGM. He also ceases to be the Chairman/Member of the following Board Committees of the Company, with effect from the conclusion of the ensuing AGM: a) Audit Committee – Member b) Nomination and Remuneration Committee – Member c) Stakeholders’ Relationship Committee - Chairman The Board places on record its appreciation for the contributions made by Mr. Desai during his tenure as Chairman and Director of the Company. The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the SEBI Listing Regulations are provided in Annexure C, enclosed herewith. 3. Appointment of Mr. Raghu Kumar (DIN: 01983106) as an Additional Director (Non-Executive and Independent) of the Company: Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has approved the appointment of Mr. Raghu Kumar (DIN: 01983106) as an Additional Director (Non-Executive and Independent) with effect from August 06, 2026 and as an Independent Director for first term of three (3) consecutive years, with effect from August 06, 2026, subject to approval of Members of the Company. Mr. Raghu Kumar is not debarred from holding the office of a Director by virtue of any Securities and Exchange Board of India (‘SEBI’) order and in accordance with BSE Circular No. LIST/COMP/14/2018-19 dated June 20, 2018 and NSE Circular No. NSE/CML/2018/02 dated June 20, 2018, or any such other authority, and he is not related to any Director(s) or Key Managerial Personnel(s) of the Company. The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the SEBI Listing Regulations are provided in Annexure C, enclosed herewith. 4. Appointment of Chairman of the Company: In view of the retirement of Mr. Berjis Desai (DIN: 00153675), Chairman and Non- Executive, Non-Independent Director of the Company, upon conclusion of the ensuing Annual General Meeting ("AGM"), and based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has approved the appointment of Mr. Satish Mehta (DIN: 00118691), Managing Director & CEO as the Chairman of the Company with effect from the conclusion of the ensuing AGM. The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the SEBI Listing Regulations are provided in Annexure C, enclosed herewith. Emcure Pharmaceuticals Limited Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251 Emcure 5. Appointment of Chief Operation Officer of the Company: Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has approved the appointment of Mr. Samit Mehta, Whole- time Director (DIN: 00332562) as the Chief Operating Officer (COO) of the Company with immediate effect, in addition to his existing position as Whole-time Director. 6. Re-constitution of the following Committees of the Board: The Board has approved the re-constitution of the following Committees, with effect from conclusion of ensuing Annual General Meeting, enclosed as Annexure D: a) Audit Committee b) Nomination and Remuneration Committee c) Stakeholders’ Relationship Committee The meeting of the Board of Directors of the Company commenced at 12:50 p.m. (IST) and concluded at 13:30 p.m. (IST). You are requested to take the above information on your records. Thanking you, For Emcure Pharmaceuticals Limited Amruta Yangalwar Company Secretary & Compliance Officer ICSI Membership No.: A25687 Encl: As above Emcure Pharmaceuticals Limited Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251 Annexure- A 8th Floor, Unit 802, Godrej Koregaon Park BS R & Co. LLP North Main Road, Mundhwa Pune, Maharashtra, 411001 Chartered Accountants Telephone: +91 (20) 4061 2200 Limited Review Report on unaudited consolidated financial results of Emcure Pharmaceuticals Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended To the Board of Directors of Emcure Pharmaceuticals Limited 1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Emcure Pharmaceuticals Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 June 2026 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). 2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regu [Showing first 8,000 characters — download PDF for full document]